Navigation Links
Vaccines in Biological Technology

Novavax Reports Second Quarter 2009 Financial Results

... market authorization of the VLP-based influenza vaccines in the European Union, which is targeted for ... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases ... produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing ...

GeoVax Labs, Inc. Provides Clinical Studies Update

... other vaccine candidates. GeoVax's DNA and MVA vaccines are used in a prime-boost protocol in which ... manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human ... issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to ...

ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery

... has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of ... David Evans, chairman of Scancell. DNA-based vaccines have gained popularity due to promising results ... for simple alternative methods of delivering DNA vaccines DepoVax(TM) is a vaccine-enhancement and ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead ... products in development are recombinant subunit vaccines designed to protect against the lethal effects of ... significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and ...

Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose

... on developing highly effective and affordable vaccines based on proprietary manufacturing technologies ... The challenge of current pandemic influenza vaccines is they have to match the circulating strain in ... in June and support our belief that our influenza vaccines are also capable of providing protection against ...

Sanofi-aventis Announces Second Quarter 2009 Results

... Growth of 18.4% for the vaccines business excluding H5N1 contracts(2) ... growth opportunities : significant boost to our vaccines business in Emerging Markets with the ... and at constant exchange rates). Human vaccines Second-quarter consolidated net sales for the ...

Vi typhoid vaccine proves highly effective in young children

... exclusively to development and deployment of new vaccines primarily for people in developing countries. ... through vaccines. Safe and effective vaccines against typhoid fever exist, but they are used ... by the World Health Organization for use of Vi vaccines in developing countries, its use has been ...

Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)

... Ltd. (NYSE AMEX: SVA ), a leading provider of vaccines in China, today announced that it has initiated ... Therefore, we are examining H1N1 vaccines that provide safety, efficacy, and high volume ... infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) ...

Cadila Pharmaceuticals Launches Joint Venture With Novavax in India

... influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based ... long and successful effort to bring important new vaccines and other pharmaceutical products to the people ... produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing ...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead ... products in development are recombinant subunit vaccines designed to protect against the lethal effects of ... significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and ...

GeoVax Labs, Inc. Announces Resignation of Director

... manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human ... issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to ... the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment ...

Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain

... groups to develop pandemic and seasonal flu vaccines and establish its only in-border facility. This ... being launched to develop safe and effective flu vaccines to serve the entire population of Spain. ... VLP vaccine technology to commercialize flu vaccines in Spain and Portugal, and non-exclusive licenses ...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead ... products in development are recombinant subunit vaccines designed to protect against the lethal effects of ... significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and ...

Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply

... Pa., June 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: ... able to increase the supply of its Hib-containing vaccines to enable the return to a full series of ... cause hospitalization or even death. Before Hib vaccines were available, Hib was the most common cause of ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... PA. This TB data demonstrated that vaccines utilizing the L.E.A.P.S. vaccine technology with ... in Baltimore showed that CEL-SCI's L.E.A.P.S. vaccines can activate and cause human blood monocyte cells ... These results were obtained for L.E.A.P.S. vaccines against herpes simplex and HIV. The ...

AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS

... technology, which delivers innovative vaccines with very specific properties. The firm has ... the development of candidates for therapeutic vaccines against Alzheimer's, Parkinson's and ... AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat ...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois

... biopharmaceutical company developing human vaccines for diseases caused by the HIV-1 (Human ... the clinical trials of the DNA/MVA and MVA/MVA vaccines developed by GeoVax scientists, in collaboration ... region to participate in clinical trials of vaccines with the potential to protect against HIV/AIDS ...

Sinovac Completes Construction of H1N1 Virus Seed Bank

... SVA ), a leading developer and provider of vaccines in China, announced today that it has completed ... development, manufacture and commercialization of vaccines that protect against human infectious diseases. ... for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, ...

Lethality of H1N1 Influenza Virus Increasing According to Latest Analysis of Virus Peptide Genomic Data

... and market novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases ... and HIV. The company's predictive products and vaccines in development are based upon the company's ... (FluForecast(TM)) and is designing synthetic vaccines specifically tailored to combat a given strain ...

Sinovac Begins the Production of Influenza A (H1N1) Vaccine

... SVA ), a leading developer and provider of vaccines in China, announced today that it begins the ... to offer our expertise in supplying preventative vaccines to the national and local authorities as they ... of the virus seed. In order to supply enough vaccines to protect the public within a reasonable period ...

Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus

... in the evaluation of alternative investigational vaccines against this emerging threat to public health." ... technology that can lead to rapid production of vaccines is important to reduce the spread of the virus ... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases ...

China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation

... SVA ), a leading developer and provider of vaccines in China, announced today that China's Vice ... that we can play a significant role in providing vaccines against influenza A (H1N1) virus. Once we ... attendees on the global capacity of influenza vaccines and ensure that ...

Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine

... 27 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: ... the world's leading manufacturer of influenza vaccines to begin the production process for an A(H1N1) ... New York (NYSE: SNY ). Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more ...

AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support

... (cholesteryl ester transfer protein). Following vaccines for Alzheimer's disease and Parkinson's disease, ... "So far, we have announced the development of vaccines for three diseases - Alzheimer's, Parkinson's and ... AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic ... In both cases, the addition of CEL-1000 to the vaccines resulted in significant increases in the ... either alone as a therapy or as an adjuvant to vaccines under development for the treatment of H1N1 ...

Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate

... of research. Currently, pandemic flu vaccines are prepared by a slow and inefficient process ... culture using a standard process. Vaxart vaccines are novel in several ways, including the fact ... as well as creating oral alternatives to current vaccines such as annual influenza and HPV. The company ...

Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data

... rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict ... and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases ... and HIV. The company's predictive products and vaccines in development are based upon the company's ...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

... and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead ... products in development are recombinant subunit vaccines designed to protect against the lethal effects of ... significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and ...

Medicago succesfully expresses VLP antigen for A H1N1 strain

... on developing highly effective and affordable vaccines based on proprietary manufacturing technologies ... to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) ... technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using ...

Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results

... Ltd. (Amex: SVA ), a leading provider of vaccines in China, today announced that it will host a ... development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) ...

Novavax Reports First Quarter 2009 Financial Results

... progress in advancing our VLP based influenza vaccines over the past three years. The recent emergence ... biotechnology company creating novel vaccines to address a broad range of infectious diseases ... produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing ...

GeoVax Labs, Inc. Announces First Quarter Financial Results

... towards the research and development of our vaccines program; human clinical trials support and ... biotechnology company focused on developing human vaccines for diseases caused by HIV-1 (Human ... issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to ...

Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate

... approach may offer an advantage over existing vaccines which contain mostly HA with variable and ... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases ... produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing ...

First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide

... have stated that conventionally developed H1N1 vaccines will not be ready for many months. This key ... ability to swiftly identify, and make molecular vaccines based on, key sub-sequences of the virus genome ... used to manufacture synthetic conserved Replikin vaccines against both these influenza strains, Replikins ...

Sinovac Biotech Ltd. Files Annual Report on Form 20-F

... SVA ), a leading developer and provider of vaccines in China, today announced that it has filed its ... development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) ...

Sinovac Initiates Preparatory Activities for Swine Flu Vaccine

... SVA ), a leading developer and provider of vaccines in China, today announced that the Company has ... development, manufacture and commercialization of vaccines that protect against human infectious diseases. ... for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, ...

Novavax Announces Early Retirement of $17 Million of Convertible Debt

... on the core mission of developing important new vaccines that can make a significant impact on human ... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases ... produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing ...

Medicago initiates work on Swine Flu strain

... on developing highly effective and affordable vaccines based on proprietary manufacturing technologies ... to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) ... technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... Peptide-based vaccines could prove efficacious for both prophylactic and ... that preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand ... it was recently presented that the L.E.A.P.S. vaccines work on human cells and that the ....

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... as well as enhance the effectiveness of vaccines VIENNA, Va., April 27 /PRNewswire-FirstCall/ ... Conference in Baltimore which demonstrates how vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope ... and colleagues showed that CEL-SCI's L.E.A.P.S. vaccines can activate and cause human blood monocyte cells ...
Other Contents
(Date:7/22/2014)... in modifying properties of nanomaterials for application in devices ... recent innovative studies conducted by scientists from the National ... a simple, efficient and low cost technique involving a ... Professor Sow Chorng Haur from the Department of Physics ... properties of two different types of materials can be ...
(Date:7/22/2014)... NY -- As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature , point to biological ... lead to new approaches to treating the disorder, which ...
(Date:7/22/2014)... habitats and trees and not just asphalt and recreation ... University of Colorado Boulder study. , Working on class ... benefits for youth, according to a paper published in ... is one of the first of its kind to ... settings and stress. , "Many schools already offer stress ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 Air Conditioning ... are now an authorized Daikin comfort pro dealer. This ... Daikin indoor heating and cooling system equipment. Only a ... is thoroughly reviewed before being approved. , Daikin co-developed ... in the Split System Air Conditioning Market. They are ...
(Date:7/22/2014)... The 2014 Warrior-Family Symposium (WFS) ... Building and International Trade Center in Washington, D.C. ... Civilian Communities,” will be held from 8:30 a.m. ... and cohosted by the Military Officers Association of ... (NDIA). USAA is the Executive Sponsor of the ...
(Date:7/22/2014)... York, NY (PRWEB) July 22, 2014 ... http://www.xareltolawsuitcenter.com/ ) that alleges the death of ... caused by the blood thinner, Bernstein Liebhard LLP reports. ... U.S. District Court for the Southern District of ... in January 2012, and suffered a subdural hemorrhage the ...
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Tomas Ganz, ... Angeles with the 2014 E. Donnall Thomas Lecture for ... of the iron-regulatory hormone hepcidin and investigation of its ... Nobel Prize Laureate and past Society president E. Donnall ... have represented a paradigm shift or significant discovery in ...
(Date:7/22/2014)... of the Clean Plate Club you eat pretty much ... A new Cornell University study shows that the average ... his or her plate. "If you put it ... Wansink Ph.D., author of the forthcoming book, Slim by Design, ... Brand Lab. , Wansink and co-author Katherine Abowd Johnson analyzed ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
Other TagsOther Tags